Treatment Resistant Depression with Loss of Antidepressant Response: Rapid-Acting Antidepressant Action of Dextromethorphan, A Possible Treatment Bridging Molecule
- PMID:27738380
- PMCID: PMC5044468
Treatment Resistant Depression with Loss of Antidepressant Response: Rapid-Acting Antidepressant Action of Dextromethorphan, A Possible Treatment Bridging Molecule
Abstract
Dextromethorphan (DM) may have ketamine-like rapid-acting, treatment-resistant, and conventional antidepressant effects.1,2 This reports our initial experience with DM in unipolar Major Depressive Disorder (MDD). A patient with treatment-resistant MDD (failing adequate trials of citalopram and vortioxetine) with loss of antidepressant response (to fluoxetine and bupropion) twice experienced a rapid-acting antidepressant effect within 48 hours of DM administration and lasting 7 days, sustained up to 20 days with daily administration, then gradually developing labile loss of antidepressant response over the ensuing 7 days. Upon full relapse in DSM-5 MDD while taking 600 mg/day of the strong CYP2D6 inhibitor bupropion XL, a 300 mg oral loading dose of DM was given, followed by 60 mg po bid after an additional dose-finding period, without side effects. DM exhibited a ketamine-like rapid-acting antidepressant effect, thought to be mediated by mTOR activation (related to NMDA PCP site antagonism, sigma-1 and beta adrenergic receptor stimulation) and 5HTT inhibition, resulting in AMPA receptor trafficking, and dendritogenesis, spinogenesis, synaptogenesis, and increased neuronal survival (related to NMDA antagonism and sigma-1 and mTOR signaling). This report appears to be the first report of a rapid-acting effect in unipolar MDD and adds to antidepressant effects observed in the retrospective chart review of 77 patients with Bipolar II Disorder (Kelly and Lieberman 2014). If replicated, there is some reason to think that the administration of other agents with DM, such as lithium or D-cycloserine, might prolong the duration of the rapid-antidepressant effect.
Keywords: N-methyl-D-aspartate; TOR serine – threonine – kinases; antidepressant agents; aripiprazole; depressive disorder; ketamine; receptors; receptors – AMPA; serotonin uptake inhibitors; sigma; treatment – resistant.
Similar articles
- An extension of hypotheses regarding rapid-acting, treatment-refractory, and conventional antidepressant activity of dextromethorphan and dextrorphan.Lauterbach EC.Lauterbach EC.Med Hypotheses. 2012 Jun;78(6):693-702. doi: 10.1016/j.mehy.2012.02.012. Epub 2012 Mar 7.Med Hypotheses. 2012.PMID:22401777
- Dextromethorphan as a potential rapid-acting antidepressant.Lauterbach EC.Lauterbach EC.Med Hypotheses. 2011 May;76(5):717-9. doi: 10.1016/j.mehy.2011.02.003. Epub 2011 Mar 1.Med Hypotheses. 2011.PMID:21367535
- A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.Naughton M, Clarke G, O'Leary OF, Cryan JF, Dinan TG.Naughton M, et al.J Affect Disord. 2014 Mar;156:24-35. doi: 10.1016/j.jad.2013.11.014. Epub 2013 Dec 10.J Affect Disord. 2014.PMID:24388038Review.
- Involvement of AMPA receptors in the antidepressant-like effects of dextromethorphan in mice.Nguyen L, Matsumoto RR.Nguyen L, et al.Behav Brain Res. 2015 Dec 15;295:26-34. doi: 10.1016/j.bbr.2015.03.024. Epub 2015 Mar 21.Behav Brain Res. 2015.PMID:25804358
- Ketamine for Major Depressive Disorder.Costi S.Costi S.Curr Top Behav Neurosci. 2024;66:131-147. doi: 10.1007/7854_2023_453.Curr Top Behav Neurosci. 2024.PMID:37922100Review.
Cited by
- Combination of dextromethorphan and memantine in treating bipolar spectrum disorder: a 12-week double-blind randomized clinical trial.Lee SY, Wang TY, Chen SL, Chang YH, Chen PS, Huang SY, Tzeng NS, Wang LJ, Lee IH, Chen KC, Yang YK, Hong JS, Lu RB.Lee SY, et al.Int J Bipolar Disord. 2020 Mar 2;8(1):11. doi: 10.1186/s40345-019-0174-8.Int J Bipolar Disord. 2020.PMID:32115672Free PMC article.
- N-Substituted-3-alkoxy-derivatives of dextromethorphan are functional NMDA receptor antagonists in vivo: Evidence from an NMDA-induced seizure model in rats.Witkin JM, Cerne R, Newman AH, Izenwasser S, Smith JL, Tortella FC.Witkin JM, et al.Pharmacol Biochem Behav. 2021 Apr;203:173154. doi: 10.1016/j.pbb.2021.173154. Epub 2021 Feb 17.Pharmacol Biochem Behav. 2021.PMID:33609599Free PMC article.
- Improvement of depressive symptoms, after a suicide attempt, with dextromethorphan/bupropion combination treatment in a patient with treatment-resistant depression and psychiatric comorbidities.Pedraz-Petrozzi B, Deuschle M, Gilles M.Pedraz-Petrozzi B, et al.Clin Case Rep. 2023 Mar 7;11(3):e7045. doi: 10.1002/ccr3.7045. eCollection 2023 Mar.Clin Case Rep. 2023.PMID:36911631Free PMC article.
- Potential Negative Effects of Dextromethorphan as an Add-On Therapy to Methylphenidate in Children With ADHD.Chuang WC, Yeh CB, Wang SC, Pan PY, Shyu JF, Liu YP, Gau SS, Lu RB.Chuang WC, et al.Front Psychiatry. 2019 Jun 26;10:437. doi: 10.3389/fpsyt.2019.00437. eCollection 2019.Front Psychiatry. 2019.PMID:31333511Free PMC article.
- Next-Generation Personalized Medicine: Implementation of Variability Patterns for Overcoming Drug Resistance in Chronic Diseases.Ilan Y.Ilan Y.J Pers Med. 2022 Aug 10;12(8):1303. doi: 10.3390/jpm12081303.J Pers Med. 2022.PMID:36013252Free PMC article.Review.
References
- Lauterbach EC. Dextromethorphan as a potential rapid-acting antidepressant. Med Hypotheses. 2011;76(5):717–719. - PubMed
- Lauterbach EC. An extension of hypotheses regarding rapid–acting, treatment—refractory, and conventional antidepressant activity of dextromethorphan and dextrorphan. Med Hypotheses. 2012;78(6):693–702. - PubMed
- Werling LL, Keller A, Frank JG, Nuwayhid SJ. A comparison of the binding profiles of dextromethorphan, memantine, fluoxetine, and amitriptyline: treatment of involuntary emotional expression disorder. Exp Neurol. 2007;207:248–257. - PubMed
- Lauterbach EC, Shiillcutt SD, Phillips DE. Dextromethorphan and dextrorphan as heuristic rapid-acting, conventional, and treatment-resistant antidepressants, with substance abuse considerations. In: Preedy VL, editor. Neuropathology Of Drug Addictions And Substance Misuse. Amsterdam, Netherlands: Academic Press, Elsevier B.V.; 2016. pp. 707–717.
- Lee SY, Chen SL, Chang YH, Chen SH, Chu CH, Huang SY, Tzeng NS, Wang CL, Lee IH, Yeh TL, Yang YK, Lu RB. The DRD2/ANKK1 gene is associated with response to add-on dextromethorphan treatment in bipolar disorder. J Affect Disord. 2012;138(3):295–300. - PubMed
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous